Form 4: Vericel Corp Executive Jonathan Hopper Reports Stock Transactions
SEC Form 4
Chief Medical Officer Jonathan Hopper reports acquisition and disposal of Vericel Corp stock and restricted stock units (RSUs) related to vesting and tax obligations.
Summary
- On February 24, 2025, Jonathan Hopper, Chief Medical Officer of Vericel Corp, reported transactions involving the company's stock and Restricted Stock Units (RSUs).
- Hopper acquired 1,500 shares of common stock through the vesting of RSUs granted on February 22, 2024, and deferred 50% of the vested shares (1,500 shares) into Phantom Stock under the Vericel Corporation Deferred Compensation Plan.
- An additional 1,500 shares were acquired due to RSU vesting on the same date.
- 636 shares were disposed of to cover tax withholding requirements related to the RSU vesting at a price of $52.33 per share.
- Following these transactions, Hopper directly owns 66,101 shares of Vericel Corp common stock and 9,000 Restricted Stock Units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports routine stock transactions related to executive compensation. There is no indication of positive or negative sentiment towards the company's prospects.
Future Outlook
The remaining RSUs will vest in annual installments on February 22, 2026, February 22, 2027, and February 22, 2028.
Industry Context
This filing is a routine disclosure of insider transactions, which are common for executives receiving stock-based compensation. It provides transparency into management's holdings and trading activity, which investors monitor for insights into executive sentiment and potential future performance.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives, ensuring compliance with SEC regulations.
- Companies like Amgen, Biogen, and Gilead Sciences also have executives who regularly file Form 4s for similar transactions related to stock options and RSUs.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
- Shareholders may monitor such filings for insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| February 22, 2024 | Date of RSU grant to Jonathan Hopper. |
| February 24, 2025 | Date of reported transactions: RSU vesting, stock acquisition, and tax-related disposal. |
| February 22, 2026 | Next RSU vesting installment date. |
| February 22, 2027 | Next RSU vesting installment date. |
| February 22, 2028 | Next RSU vesting installment date. |
| February 26, 2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.